Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant toripalimab after surgery for PD-L1-positive resected non-small cell lung cancer
ChiCTR2600132065Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: 3-year disease-free survival rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600132065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132065.